Mutations in the SRSF2 gene occur in 5–25% of patients with acute myeloid leukemia (AML) [1–3], in 17% of patients with myelodysplastic syndromes (MDS) [4], and up to 50% of patients with chronic myelomonocytic leukemia (CMML) [5]. This evidence concerns the gene SRSF2 and myelodysplastic syndrome.